Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DNA X, Inc.SONM · Entity 8261 | Director · Chief Executive Officer | February 06, 2025 | February 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DNA X, Inc.
Report date February 06, 2025 · Filed February 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 269,388 |
Reported balance
After 2025-02-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-02-06 · Grant · Acquired 63,604 · Balance 269,388 F1: Represents the grant of restricted stock units that vest in two equal installments on the 90th and 180th day following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2: Consists of (i) 205,784 shares of common stock and (ii) 63,604 unvested restricted stock units. F3: The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest in two equal installments on the 90th and 180th day following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.
F2: Consists of (i) 205,784 shares of common stock and (ii) 63,604 unvested restricted stock units.
F3: The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2025 Filed Feb 11, 2025 02:30 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 63,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-005766 · ownership.xml · nonDerivative · entry 1 Liu Hao Peter · CIK 0001925315 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 269,388 F1 · shares: Represents the grant of restricted stock units that vest in two equal installments on the 90th and 180th day following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 205,784 shares of common stock and (ii) 63,604 unvested restricted stock units. F3 · balance_after: The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| August 23, 2023 Filed Aug 24, 2023 01:39 UTC | DNA X, Inc. SONM · Entity 8261 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001493152-23-030021 · ownership.xml · derivative · entry 2 Liu Hao Peter · CIK 0001925315 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,014,419 Underlying: Common Stock · 1,000,000 shares Expires 2032-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Consists of (i) 254,505 vested stock options and (ii) 2,759,914 stock options that will vest in eleven equal quarterly installments from October 14, 2023 to April 14, 2026. The options become exercisable upon vesting. F1 · balance_after: Consists of (i) 254,505 vested stock options and (ii) 2,759,914 stock options that will vest in eleven equal quarterly installments from October 14, 2023 to April 14, 2026. The options become exercisable upon vesting. Read SEC document |
| August 23, 2023 Filed Aug 24, 2023 01:39 UTC | DNA X, Inc. SONM · Entity 8261 | Exercise / conversionCommon Stock | 1,000,000 | $0.42 | $419,000.00 |
DisclosureSEC source: 0001493152-23-030021 · ownership.xml · nonDerivative · entry 1 Liu Hao Peter · CIK 0001925315 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,057,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 02:45 UTC | DNA X, Inc. SONM · Entity 8261 | GrantEmployee Stock Option (Right-to-Buy) · Derivative | 4,014,419 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001493152-22-033223 · ownership.xml · derivative · entry 1 Liu Hao Peter · CIK 0001925315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014,419 Underlying: Common Stock · 4,014,419 shares Expires 2032-10-26 F1 · derivative.exercise_date: The options vest over a four-year period, with one quarter (1/4) of the options vesting on April 14, 2023 (the one-year anniversary of the date of the Reporting Person's appointment as CEO of Sonim Technologies, Inc.), and all remaining options vesting in equal quarterly installments in the amount of one-twelfth (1/12) of the remaining options amount thereafter. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 00:59 UTC | DNA X, Inc. SONM · Entity 8261 | PurchaseCommon Stock | 952,381 | $0.84 | $800,000.04 |
DisclosureSEC source: 0001493152-22-019364 · ownership.xml · nonDerivative · entry 1 Liu Hao Peter · CIK 0001925315 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,059,867 F1 · shares: Represents shares issued to the reporting person as a designee of AJP Holding Company, LLC in the first closing pursuant to the subscription agreement dated April 13, 2022 by and between the AJP Holding Company, LLC and Sonim Technologies, Inc. F1 · price: Represents shares issued to the reporting person as a designee of AJP Holding Company, LLC in the first closing pursuant to the subscription agreement dated April 13, 2022 by and between the AJP Holding Company, LLC and Sonim Technologies, Inc. F1 · balance_after: Represents shares issued to the reporting person as a designee of AJP Holding Company, LLC in the first closing pursuant to the subscription agreement dated April 13, 2022 by and between the AJP Holding Company, LLC and Sonim Technologies, Inc. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.